-
2 days ago | 
gamehype.co.uk | Kyle Doherty
“Ours is the new flesh…”Hailing from Wloclawek, Poland is indie dev: Woodland Games, with their hybrid horror-sim title: Autopsy Simulator.
-
6 days ago | 
onclive.com | Kyle Doherty
Ciltacabtagene autoleucel (cilta-cel; Carvykti) has solidified its status as a standard-of-care (SOC) treatment for patients with lenalidomide(Revlimid)-refractory multiple myeloma after 1 to 3 previous lines of therapy, according to María-Victoria Mateos, MD, PhD.
-
6 days ago | 
onclive.com | Kyle Doherty
CommentaryArticleApril 18, 2025Fact checked by:Juan Carlos Hernández-Boluda, MD, PhD, discusses the development of an EBMT machine learning model for predicting allo-HCT risk in myelofibrosis.
-
1 week ago | 
onclive.com | Kyle Doherty
Pre-existing cytopenias are one of many factors that will influence the selection between the 4 JAK inhibitors holding indications from the FDA for the treatment of patients with myelofibrosis, according to Jamile M. Shammo, MD, who added that in addition to disease symptomatology, the target of each agent should be considered, as it can dictate the toxicity profile patients will face.
-
1 week ago | 
onclive.com | Kyle Doherty
The PD-L1 IHC 22C3 pharmDx assay (Code SK006) has received European In Vitro Diagnostic Regulation (IVDR) certification to aid in the identification of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma patients who may be eligible for treatment with pembrolizumab (Keytruda).1 The assay is indicated for exclusive use with the Agilent Autostainer Link 48 advanced staining solution.
-
1 week ago | 
onclive.com | Kyle Doherty
BTK inhibitor refractoriness and lower platelet counts prior to lymphodepletion were significant predictors of overall survival (OS) in patients with mantle cell lymphoma (MCL) who received brexucabtagene autoleucel (brexu‐cel; Tecartus) in a real-world setting, according to data from the observational, prospective CART-SIE study (NCT06339255) published in the British Journal of Haematology.1 Findings demonstrated that patients who received the CAR T-cell therapy and were BTK inhibitor...
-
1 week ago | 
oncnursingnews.com | Kyle Doherty
Some social determinants of health, including heightened financial needs and stress levels, were linked to greater rates of psychoneurological symptoms in survivors of breast cancer, according to data presented at the 50th Annual Oncology Nursing Society Congress.
-
2 weeks ago | 
onclive.com | Kyle Doherty
Certain social determinants of health, such as heightened financial needs and stress levels, were associated with increased psychoneurological symptoms among patients with breast cancer who were disease survivors, according to data presented during the 50th Annual Oncology Nursing Society Congress.
-
2 weeks ago | 
onclive.com | Kyle Doherty
In patients with renal cell carcinoma (RCC), clonal neoantigen load (CNL) was significantly associated with exceptional responses to PD-1/PD-L1 and CTLA-4 combination therapy and tertiary lymphoid structure (TLS) formation was associated with these exceptional responses to PD-1/PD-L1 and VEGF inhibitor combination treatment, according to findings from a retrospective study published in Nature Cancer.1 “Treatment [for patients with RCC] has evolved greatly over the past couple of years with...
-
2 weeks ago | 
onclive.com | Kyle Doherty
The treatment paradigm of relapsed/refractory (R/R) follicular lymphoma has undergone a drastic transformation in recent years with the FDA approval of lenalidomide (Revlimid) plus rituximab (Rituxan) offering a platform for investigators to build additional combination regimens in the second-line setting.
